U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 150 points on Monday.The Dow traded up 0.40% to 42,825.71 while the NASDAQ rose 0.02% to 19,215.06. The S&P 500 also rose, gaining, 0.13% to 5,965.84.Check This Out: Top 3 Tech And Telecom Stocks That May Rocket Higher This MonthLeading and Lagging SectorsConsumer staples shares rose by 0.1% on Monday.In trading on Monday, energy stocks dipped by 1.5%.Top HeadlineGlobal Ship Lease, Inc. GSL reported upbeat results f ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2025 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from _________to___________ Commission File Number: 001-12555 PROTAGENIC THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 06-1390 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Ticker symbol(s) Name of each exchange on which registered Common Stock, par value $0.0001 PTIX Nasdaq Capital Market Common Stock Purchase Warrant PTIXW Nasdaq Capital Market Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ Emerging Growth Company ☐ FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the q ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Ticker symbol(s) Name of each exchange on which registered Common Stock, par value $0.0001 PTIX Nasdaq Capital Market Common Stock Purchase Warrant PTIXW Nasdaq Capital Market FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2024 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of ...

(Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2024 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q For the transition period from _________to___________ Commission File Number: 001-12555 PROTAGENIC THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 06-1390 ...

Protagenic Therapeutics, Inc. (NASDAQ:PTIX) Q4 2023 Earnings Conference Call April 1, 2024 4:30 PM ET Company Participants Alex Arrow - CFO Garo Armen - Executive Chairman Andrew Slee - COO Bob Stein - CMO Conference Call Participants William Wood - B. Riley Securities Operator Greetings. Welcome to the Protagenic Therapeutics' Fourth Quarter and Fiscal Year 2023 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Opera ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For fiscal year ended: December 31, 2023 Commission file number: 001-12555 Protagenic Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 06-1390025 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 149 Fifth Avenue New York, New York 10010 (Address of principal execu ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from _________to___________ Commission File Number: 001-12555 PROTAGENIC THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 06-1390025 (State or other jurisdiction of (I.R.S. Em ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2023 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from _________to___________ Commission File Number: 001-12555 PROTAGENIC THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 06-13900 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2023 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from _________to___________ Commission File Number: 001-12555 Delaware 06-1390025 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) I ...